The Purpose of this study is to provide patients with hyperphenylalaninemia (HPA) due to
Phenylketonuria (PKU) access to sapropterin dihydrochloride and to collect more information
about the safety of the drug in an expanded access program (EAP) until commercial product is
available.
Minimum age: 9 Years.
Maximum age: N/A.
Gender(s): Both.
Los Angeles, California, United States
Orange, California, United States
San Diego, California, United States
Stanford, California, United States
Denver, Colorado, United States
Gainseville, Florida, United States
Tampa, Florida, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Louisville, Kentucky, United States
New Orleans, Louisiana, United States
Bangor, Maine, United States
Boston, Massachusetts, United States
Minneapolis, Minnesota, United States
Columbia, Missouri, United States
Kansas City, Missouri, United States
St. Louis, Missouri, United States
Newark, New Jersey, United States
Manhasset, New York, United States
Rochester, New York, United States
Stony Brook, New York, United States
Valhalla, New York, United States
Akron, Ohio, United States
Columbus, Ohio, United States
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Florence, South Carolina, United States
Sioux Falls, South Dakota, United States
Galveston, Texas, United States
Houston, Texas, United States
Salt Lake City, Utah, United States
Charlottesville, Virginia, United States
Norfolk, Virginia, United States
Madison, Wisconsin, United States
Milwakee, Wisconsin, United States